BioCentury | Dec 9, 2020
Deals
Reneo to start pivotal trial in mitochondrial diseases, build orphan pipeline with Novo, Abingworth-led $95M series B
...Lundbeckfonden Ventures, as well as RiverVest.TARGETSPPARδ - Peroxisome proliferation activated receptor δ
Paul Bonanos
REN001, HPP593
Reneo Pharmaceuticals Inc.
Peroxisome proliferation activated receptor (PPAR) delta...